Q-omics provides the consensus-scored WARS1 profile across patient tissues and cancer cell-line models. WARS1 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, WARS1 is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, WARS1 protein abundance shows 25,971 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight UVM, HNSC, and LUAD as cancer lineages where WARS1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for WARS1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes WARS1 survival associations across molecular data types. WARS1 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (5) and mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible WARS1 RNA expression–survival associations across cancer types. High WARS1 expression shows unfavorable associations in UVM, KICH and LUSC, but favorable associations in SKCM, OV and CESC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for WARS1 RNA expression.
This table summarizes WARS1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 9. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for WARS1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. WARS1 shows lower tumor expression in LUSC and KICH and higher tumor expression in HNSC, STAD, LIHC and THCA. The HNSC box plot shows higher WARS1 RNA expression in tumor versus normal tissue (log2 FC = +2.071, t-test p < 0.001).
This table shows molecular features associated with WARS1 in patient tissues and cancer cell lines. In patient samples, WARS1 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, WARS1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and UPPER_AERODIGESTIVE_TRACT.
